Royal Bank of Canada Reiterates Sector Perform Rating for Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals (NASDAQ:INO)‘s stock had its “sector perform” rating restated by stock analysts at Royal Bank of Canada in a research note issued on Wednesday,Benzinga reports. They currently have a $5.00 price target on the biopharmaceutical company’s stock. Royal Bank of Canada’s price objective suggests a potential upside of 156.41% from the company’s current price.

Several other research firms have also recently issued reports on INO. StockNews.com cut shares of Inovio Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Monday. Oppenheimer lowered their target price on shares of Inovio Pharmaceuticals from $15.00 to $13.00 and set an “outperform” rating on the stock in a research note on Wednesday. Finally, HC Wainwright reiterated a “neutral” rating and issued a $3.00 target price on shares of Inovio Pharmaceuticals in a research note on Wednesday, March 19th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, Inovio Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $9.75.

Inovio Pharmaceuticals Trading Up 3.7%

Shares of INO stock opened at $1.95 on Wednesday. The stock has a market capitalization of $71.51 million, a P/E ratio of -0.49 and a beta of 1.40. The firm’s 50 day moving average is $1.80 and its 200 day moving average is $2.53. Inovio Pharmaceuticals has a 12 month low of $1.42 and a 12 month high of $13.44.

Inovio Pharmaceuticals (NASDAQ:INO) last announced its quarterly earnings results on Tuesday, May 13th. The biopharmaceutical company reported ($0.51) EPS for the quarter, beating analysts’ consensus estimates of ($0.74) by $0.23. The business had revenue of $0.07 million for the quarter, compared to analysts’ expectations of $0.01 million. On average, equities analysts predict that Inovio Pharmaceuticals will post -4.23 EPS for the current year.

Institutional Trading of Inovio Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Nomura Holdings Inc. purchased a new stake in shares of Inovio Pharmaceuticals during the 1st quarter valued at $28,000. Freedom Investment Management Inc. purchased a new stake in shares of Inovio Pharmaceuticals during the 1st quarter valued at $31,000. Nuveen LLC purchased a new stake in shares of Inovio Pharmaceuticals during the 1st quarter valued at $168,000. Charles Schwab Investment Management Inc. raised its position in shares of Inovio Pharmaceuticals by 38.6% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 98,495 shares of the biopharmaceutical company’s stock valued at $161,000 after buying an additional 27,429 shares in the last quarter. Finally, XTX Topco Ltd raised its position in shares of Inovio Pharmaceuticals by 26.7% during the 1st quarter. XTX Topco Ltd now owns 66,169 shares of the biopharmaceutical company’s stock valued at $108,000 after buying an additional 13,939 shares in the last quarter. Hedge funds and other institutional investors own 26.79% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.